So, nirvana for most patients – although knee replacements are more painful and recovery longer – and a nice living for ...

New study shows tirzepatide reduces LV mass and heart fat in obesity-related HFpEF, potentially improving heart failure outcomes.

A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

(Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking less—but didn’t go so far as to actually prove that the medications caused people to drink less.) ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

GLP-1 therapies have demonstrated significant cardiometabolic benefits, particularly in high-risk patients with cardiovascular disease. Recent trials have shown the effectiveness of GLP-1 ...